Published in
Wiley, Arthritis and Rheumatology, 3(74), p. 475-485, 2022
DOI: 10.1002/art.42010
Links
Tools
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
Journal article published in 2022 by
Iain B. McInnes 
,
Proton Rahman,
Alice B. Gottlieb,
Elizabeth C. Hsia,
Alexa P. Kollmeier,
Xie L. Xu,
Yusang Jiang,
Shihong Sheng,
May Shawi,
Soumya D. Chakravarty ,
Désirée van der Heijde,
Philip J. Mease
,
Proton Rahman,
Alice B. Gottlieb,
Elizabeth C. Hsia,
Alexa P. Kollmeier,
Xie L. Xu,
Yusang Jiang,
Shihong Sheng,
May Shawi,
Soumya D. Chakravarty ,
Désirée van der Heijde,
Philip J. Mease
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 